Company news

ANI Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

November 2, 2021

ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock

November 2, 2021

ANI Pharmaceuticals Reports Third Quarter 2021 Results

October 31, 2021

ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome

October 31, 2021

ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021

October 28, 2021

ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021

September 19, 2021

ANI Pharmaceuticals Announces Launch of Nebivolol Tablets

September 16, 2021

ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome

August 30, 2021

ANI Pharmaceuticals Reports Second Quarter 2021 Results

August 5, 2021

ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021

July 21, 2021

ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA

July 5, 2021

ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021

June 14, 2021

ANI Pharmaceuticals Announces Details of 2021 Virtual Annual Meeting of Stockholders

May 31, 2021

ANI Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

May 26, 2021

ANI Pharmaceuticals Reports First Quarter 2021 Results

May 6, 2021

ANI Pharmaceuticals to Discuss First Quarter 2021 Financial Results on May 7, 2021

April 25, 2021

ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs

April 5, 2021

ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business

March 8, 2021

ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth

March 8, 2021

ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 18, 2021

ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth

February 16, 2021

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

February 15, 2021

ANI Pharmaceuticals Announces Launch of Prazosin Hydrochloride (“HCl”) Capsules

January 31, 2021

ANI Pharmaceuticals Announces Approval and Launch of Aminocaproic Acid Tablets

December 16, 2020

ANI Pharmaceuticals Reports Third Quarter 2020 Results

November 4, 2020

ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter 2020 Financial Results

October 28, 2020

ANI Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 9, 2020

ANI Pharmaceuticals Reports Second Quarter 2020 Results

August 5, 2020

ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio “Tony” Pera to Board of Directors

August 5, 2020

ANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive Officer

August 2, 2020

ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter 2020 Financial Results

July 29, 2020

ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets

July 5, 2020

ANI Pharmaceuticals Announces Launch of Mexiletine Hydrochloride Capsules

June 29, 2020

ANI Pharmaceuticals Provides Update on Recent Regulatory Filing

May 31, 2020

ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO

May 6, 2020

ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2020 Financial Results

April 29, 2020

ANI Receives Refusal to File Letter from FDA for Cortrophin® Gel

April 28, 2020

ANI Announces Upcoming Departure of CEO

April 13, 2020

ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL

April 12, 2020

ANI Pharmaceuticals Announces Launch of Omega-3-Acid Ethyl Esters Capsules USP

April 1, 2020

ANI Announces Launch of Polyethylene Glycol 3350, 17g/Packet

March 25, 2020

ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL

March 23, 2020

ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules

March 1, 2020

ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin® Gel sNDA to FDA in March 2020

February 26, 2020

ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2019 Financial Results

February 19, 2020

ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL

February 11, 2020

ANI Announces Launch of Tolterodine Extended-Release Capsules

January 23, 2020

ANI Pharmaceuticals Announces FDA Approval of Potassium Citrate Extended-Release Tablets USP

January 15, 2020

ANI Announces Launch of Paliperidone Extended-Release Tablets

January 13, 2020

ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd.

January 8, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 59 decks. Every deck is listed under its year.